Floatz logo

Rimiducid

Castrate Resistant Prostate Cancer (CRPC)

Poseida Therapeutics, Inc.Small moleculePhase 1Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
95/ 100

Competitive context

230 Active assets in the Castrate Resistant Prostate Cancer (CRPC) cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
Darolutamide
Bayer
Phase 3BB
Bms-907351
Rana McKay, MD
Phase 3BB

View all 50 →

Same molecule, other indications

Rimiducid is also rated in:

myelodysplastic syndromeDormant
CCC
Indicative ·
51 / 100
View asset →
inborn error of immunityDormant
CCC
Indicative ·
50 / 100
View asset →
myeloproliferative neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →